Psoriasis is a chronic inflammatory disease characterised by sharply demarcated
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …

Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis is a chronic inflammatory skin disorder, and current treatments include topical
therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate …

Background The use of monoclonal antibodies has changed the treatment of several
immune-mediated inflammatory diseases, including psoriasis. However, these large …

Emerging biologics, such as monoclonal antibodies (mAbs), are the most promising
treatment for psoriasis, while their effective delivery to the local inflammatory area of the skin …

Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …

Recent knowledge on the key role of interleukin (IL) 23/17 axis in psoriasis pathogenesis,
led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin …

Since the foundation of the European Society for Dermatological Research, pathogenesis of
psoriasis has been studied by many research groups, focusing on various compartments of …

Psoriasis is a chronic, autoimmune, and non-communicable skin disease with a worldwide
prevalence rate of 2–3%, creating an economic burden on global health. Some significant …